SAR156597 is a monoclonal antibody targeting IL-4 and IL-13 and a phase II proof of concept placebo-controlled trial is now ongoing (ClinicalTrials.gov; NCT02921971) in SSc and a phase II trial has been undertaken in idiopathic pulmonary fibrosis, which did not have positive results [45]. Here, IL13 is linked to systemic sclerosis.